
Please try another search
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform products for the treatment of neuroinflammation. The company develops JNS101, which is in Phase II trial for the treatment of Friedreich's Ataxia, a rare inherited disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS108 that is in Phase II trial for treating mild cognitive impairment/early Alzheimer’s disease. It is also involved in the development of JNS102, which is in Phase II trial for the treatment of mucopolysaccharidosis type 1; and JNS107 that is in Phase II trial for treating mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome. In addition, the company develops JNS115, which is in Phase IIa trial for the treatment of Parkinson’s disease. It has a strategic partnership with Zina Biopharmaceuticals, LLC to advance Phase 2a clinical trial to evaluate the safety, tolerability, and pharmacokinetics of Resveratrol (JOTROLTM) in individuals with Parkinson’s disease; and with Aquanova AG to develop a series of consumer-focused nutritional products targeting longevity, aging, and healthspan. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. Jupiter Neurosciences, Inc. was incorporated in 2016 and is headquartered in Jupiter, Florida.
Name | Age | Since | Title |
---|---|---|---|
Raymond Scott Turner | 65 | 2016 | Member of Scientific Advisory Board |
Li-Huei Tsai | 63 | 2016 | Member of Scientific Advisory Board |
Peter Elliott | 66 | 2016 | Member of Scientific Advisory Board |
Charbel Moussa | 53 | 2020 | Member of Scientific Advisory Board |
Allison W. Brady | 52 | 2021 | Independent Director |
W. Dalton Dietrich | 73 | 2021 | Member of Scientific Advisory Board |
Rudolph Emile Tanzi | 66 | 2019 | Co-Chairman of Scientific Advisory Board |
Nicholas H. Hemmerly | 42 | 2021 | Independent Director |
Holger Weis | 62 | 2021 | Independent Director |
Shaun P. Brothers | 46 | 2016 | Co-Founder Member of Scientific Advisory Board & Consulting Vice President of Science Research |
Julie Kampf | 62 | 2021 | Independent Director |
Claes Wahlestedt | 66 | 2016 | Co-Founder, Co-Chairman of Scientific Advisory Board & Consulting Chief Medical Officer |
Marshall Hayward | 67 | 2016 | Co-Founder, Chief Scientific Officer & Director |
Christer Rosen | 72 | 2016 | Co-Founder, CEO & Chairman of the Board |
Alison D. Silva | 46 | 2018 | President, Chief Business Officer & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review